Airsculpt Technologies Inc (AIRS)vsNovartis AG ADR (NVS)
AIRS
Airsculpt Technologies Inc
$2.54
+2.83%
HEALTHCARE · Cap: $174.25M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 37167% more annual revenue ($56.58B vs $151.82M). NVS leads profitability with a 23.9% profit margin vs -7.7%. NVS earns a higher WallStSmart Score of 51/100 (C-).
AIRS
Hold36
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.9%
Fair Value
$7.04
Current Price
$2.54
$4.50 discount
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 200.0% YoY
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
ROE of -14.1% — below average capital efficiency
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : AIRS
The strongest argument for AIRS centers on EPS Growth, Price/Book.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : AIRS
The primary concerns for AIRS are Market Cap, Debt/Equity, Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
AIRS profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
AIRS carries more volatility with a beta of 2.27 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 36/100), backed by strong 23.9% margins. AIRS offers better value entry with a 69.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Airsculpt Technologies Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Airsculpt Technologies Inc (AIRS) is a leader in the aesthetic medical technology field, recognized for its proprietary AirSculpt® procedure, which offers minimally invasive body contouring solutions while emphasizing patient safety and comfort. The company boasts a growing network of licensed practitioners and a strong focus on technological innovation, positioning itself advantageously in the expanding market for non-invasive cosmetic treatments. By responding to the rising global demand for aesthetic procedures, Airsculpt aims to enhance its market share and diversify its service offerings, thereby fostering both immediate growth and sustainable long-term value for investors.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?